RELX vs. GSK.L
RELX (RELX PLC) and GSK.L (GlaxoSmithKline plc) are both stocks. RELX operates in Publishing (Communication Services), while GSK.L operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, RELX returned 8.22%/yr vs 6.39%/yr for GSK.L. At a 0.37 correlation, their price movements are largely independent.
Performance
RELX vs. GSK.L - Performance Comparison
Loading charts...
Different Trading Currencies
RELX is traded in USD, while GSK.L is traded in GBp. To make them comparable, the GSK.L values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, RELX achieves a -17.01% return, which is significantly lower than GSK.L's 2.98% return. Over the past 10 years, RELX has outperformed GSK.L with an annualized return of 8.22%, while GSK.L has yielded a comparatively lower 6.39% annualized return.
RELX
- 1D
- -1.44%
- 1M
- -7.74%
- YTD
- -17.01%
- 6M
- -16.54%
- 1Y
- -37.62%
- 3Y*
- 2.83%
- 5Y*
- 6.77%
- 10Y*
- 8.22%
GSK.L
- 1D
- 1.43%
- 1M
- -2.75%
- YTD
- 2.98%
- 6M
- 3.30%
- 1Y
- 28.52%
- 3Y*
- 18.03%
- 5Y*
- 9.57%
- 10Y*
- 6.39%
RELX vs. GSK.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RELX RELX PLC | -17.01% | -9.60% | 16.59% | 46.09% | -13.06% | 35.47% | 0.27% | 25.28% | -11.20% | 34.97% |
GSK.L GlaxoSmithKline plc | 2.98% | 52.14% | -5.11% | 10.47% | -17.30% | 25.59% | -18.29% | 30.41% | 12.35% | -2.28% |
Correlation
The correlation between RELX and GSK.L is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.32 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.35 |
Correlation (All Time) Calculated using the full available price history since Jul 2, 2007 | 0.37 |
Over the past year, the correlation between RELX and GSK.L has dropped to 0.11 - well below their long-term average of 0.37, suggesting their price drivers have been diverging.
Fundamentals
RELX:
$60.32B
GSK.L:
£75.43B
RELX:
$2.17
GSK.L:
£1.42
RELX:
15.15
GSK.L:
13.00
RELX:
1.56
GSK.L:
0.29
RELX:
3.18
GSK.L:
2.31
RELX:
25.54
GSK.L:
4.23
RELX:
$18.99B
GSK.L:
£32.78B
RELX:
$12.35B
GSK.L:
£23.84B
RELX:
$6.05B
GSK.L:
£11.56B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RELX vs. GSK.L — Risk / Return Rank
RELX
GSK.L
RELX vs. GSK.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for RELX PLC (RELX) and GlaxoSmithKline plc (GSK.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RELX | GSK.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.38 | ||
| Sortino ratioReturn per unit of downside risk | -3.55 | ||
| Omega ratioGain probability vs. loss probability | 0.76 | 1.21 | -0.45 |
| Calmar ratioReturn relative to maximum drawdown | -0.77 | 1.53 | -2.31 |
| Martin ratioReturn relative to average drawdown | -1.44 | 3.66 | -5.11 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| RELX | GSK.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -1.26 | 1.12 | -2.38 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.30 | 0.41 | -0.11 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.37 | 0.29 | +0.08 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.32 | 0.20 | +0.12 |
Drawdowns
RELX vs. GSK.L - Drawdown Comparison
The maximum RELX drawdown since its inception was -49.91%, which is greater than GSK.L's maximum drawdown of -45.57%. Use the drawdown chart below to compare losses from any high point for RELX and GSK.L.
Loading charts...
Drawdown Indicators
| RELX | GSK.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -49.91% | -45.57% | -4.34% |
Max Drawdown (1Y)Largest decline over 1 year | -48.71% | -18.55% | -30.16% |
Max Drawdown (3Y)Largest decline over 3 years | -49.91% | -29.30% | -20.61% |
Max Drawdown (5Y)Largest decline over 5 years | -49.91% | -38.95% | -10.96% |
Max Drawdown (10Y)Largest decline over 10 years | -49.91% | -38.95% | -10.96% |
Current DrawdownCurrent decline from peak | -39.41% | -17.39% | -22.02% |
Average DrawdownAverage peak-to-trough decline | -12.27% | -13.27% | +1.00% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.11% | 7.77% | +18.34% |
Volatility
RELX vs. GSK.L - Volatility Comparison
RELX PLC (RELX) has a higher volatility of 10.97% compared to GlaxoSmithKline plc (GSK.L) at 5.93%. This indicates that RELX's price experiences larger fluctuations and is considered to be riskier than GSK.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RELX | GSK.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.97% | 5.93% | +5.04% |
Volatility (6M)Calculated over the trailing 6-month period | 27.05% | 18.38% | +8.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.94% | 25.49% | +4.45% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.67% | 23.44% | -0.77% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.40% | 22.29% | +0.11% |
Dividends
RELX vs. GSK.L - Dividend Comparison
RELX's dividend yield for the trailing twelve months is around 2.79%, less than GSK.L's 3.62% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK.L GlaxoSmithKline plc | 3.62% | 3.51% | 4.53% | 3.84% | 4.69% | 4.98% | 5.96% | 4.50% | 5.36% | 6.05% | 4.93% | 5.83% |
RELX RELX PLC | 2.79% | 2.03% | 1.68% | 1.73% | 2.42% | 2.05% | 2.39% | 1.57% | 2.68% | 2.05% | 2.55% | 2.28% |
Financials
RELX vs. GSK.L - Financials Comparison
This section allows you to compare key financial metrics between RELX PLC and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RELX vs. GSK.L - Profitability Comparison
RELX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, RELX PLC reported a gross profit of 3.07B and revenue of 4.82B. Therefore, the gross margin over that period was 63.8%.
GSK.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
RELX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, RELX PLC reported an operating income of 1.51B and revenue of 4.82B, resulting in an operating margin of 31.4%.
GSK.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
RELX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, RELX PLC reported a net income of 1.08B and revenue of 4.82B, resulting in a net margin of 22.5%.
GSK.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
RELX and GSK.L have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for RELX and GSK.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer